We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Novel Treatment Regimen Kills Leukemia Cells and Blocks Angiogenesis

By LabMedica International staff writers
Posted on 15 Jun 2010
A tandem treatment regimen for acute myelogenous leukemia (AML) succeeds by both killing cancer cells and preventing reestablishment of disrupted blood vessels.

Investigators at the University of Florida (Gainesville, FL, USA) treated mice bearing xenografts of human AML with the vascular disrupting agent, OXi4503, alone and in combination with the anti-VEGF (vascular endothelial growth factor) antibody, bevacizumab. More...


They reported in the May 14, 2010, online edition of the journal Blood that OXi4503 killed the cells at the core of AML tumors but that viable rims of leukemia cells remained and were richly vascular with increased VEGF expression. Then, bevacizumab treatment blocked VEGF expression in the endothelial tissue adjacent to the surviving leukemia cells and prevented reestablishment of the tumor.

"We have identified a new tool to dissect out the specifics of the relationship between leukemia cells and the blood vessels that supply them,” said senior author Dr. Christopher Cogle, professor of oncology at the University of Florida. "What we are offering is a brand new treatment by a very different mechanism to people who desperately need something new.”

Related Links:

University of Florida




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Chromogenic Culture System
InTray™ COLOREX™ ECC
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image: At the MHH Institute of Human Genetics: Prof. Dr. Doris Steinemann, Dr. Bernardus Aldrige Allister and Prof. Dr Monika Golas (from left). (Image Credit: Karin Kaiser/MHH)

Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer

Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.